Published in Bull Cancer on November 01, 1998
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol (2004) 3.97
ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol (2007) 2.18
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol (1996) 2.17
ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer (1998) 1.98
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer (2003) 1.90
A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics (1996) 1.75
Patient-controlled interscalene analgesia after shoulder surgery: catheter insertion by the posterior approach. Anesth Analg (2005) 1.69
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67
Prevalence of residual excessive sleepiness in CPAP-treated sleep apnoea patients: the French multicentre study. Eur Respir J (2009) 1.62
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol (2005) 1.54
Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer (1993) 1.47
[Ki67 in young patients with breast cancer]. Gynecol Obstet Fertil (2013) 1.41
[Labour epidural analgesia in Martinique: evaluation of quality and accessibility to epidural analgesia by the patients in level one obstetric clinic]. Ann Fr Anesth Reanim (2004) 1.39
Second consensus on medical treatment of metastatic breast cancer. Ann Oncol (2006) 1.37
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol (1996) 1.31
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res (2003) 1.24
Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res (1988) 1.20
Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat.haemophiles@cch.ap-hop-paris.fr. Haemophilia (2000) 1.18
Economic evaluation of cost-benefit ratio of neonatal screening procedure for phenylketonuria and hypothyroidism. J Inherit Metab Dis (1991) 1.13
Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol (1994) 1.13
Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet (1995) 1.12
A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neurooncol (2013) 1.09
Factors influencing the long-term results of endodontic treatment: a review of the literature. Int Dent J (2002) 1.07
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer (2000) 1.05
Type 1 IGF receptor in human breast diseases. Breast Cancer Res Treat (1992) 1.00
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br J Cancer (1996) 0.99
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol (2005) 0.98
The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine (1999) 0.98
[Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia]. Encephale (2002) 0.95
Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients. Ann Oncol (2005) 0.94
A French survey of 3,225 patients treated with CPAP for obstructive sleep apnoea: benefits, tolerance, compliance and quality of life. Eur Respir J (1998) 0.93
Prognostic significance of prolactin receptors in human breast cancer. Cancer Res (1987) 0.93
The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol (2012) 0.92
Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. Eur J Cancer (1997) 0.91
Insulin-like growth factor 1 receptors (IGF1-R) and IGF1 in human breast tumors. J Steroid Biochem Mol Biol (1990) 0.91
Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. Ann Oncol (2005) 0.90
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol (2000) 0.90
Analysis of p16 gene deletion and point mutation in breast carcinoma. Br J Cancer (1995) 0.90
French version of FACT-G: validation and comparison with other cancer-specific instruments. Eur J Cancer (2004) 0.89
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer (1997) 0.89
Presence of the two growth hormone receptor messenger RNA isoforms in human breast cancer. Cell Growth Differ (1995) 0.88
Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol (1990) 0.87
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer (2003) 0.86
Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. Cancer Chemother Pharmacol (2011) 0.86
Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the french context. Diabetes Metab (2000) 0.86
Presence and characterization of insulin-like growth factor 1 receptors in human benign breast disease. Eur J Cancer Clin Oncol (1988) 0.86
[Study of developing clinical outbreak and serological rebounds in children with congenital toxoplasmosis and follow-up during the first 2 years of life]. Arch Pediatr (1997) 0.85
[Male breast cancer: a review]. Bull Cancer (2009) 0.85
Characterization of insulin-like growth factor 1 receptors (IGF1-R) in human breast cancer cell lines. Bull Cancer (1989) 0.85
Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group. Cancer Chemother Pharmacol (1990) 0.85
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]. Cancer Radiother (2003) 0.84
Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2. Br J Cancer (2012) 0.84
Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers. Clin Cancer Res (1998) 0.84
[The economic and social effects of rheumatoid pelvis-spondylitis]. Rev Epidemiol Sante Publique (1982) 0.83
Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients. Br J Cancer (2010) 0.83
Prolactin receptors (PRL-R) and breast cancer. Eur J Cancer Clin Oncol (1989) 0.83
Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer. Anticancer Res (1989) 0.83
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial. Br J Cancer (2007) 0.82
Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study). Ann Oncol (2005) 0.82
Ketamine does not decrease postoperative pain after remifentanil-based anaesthesia for tonsillectomy in adults. Acta Anaesthesiol Scand (2004) 0.82
High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer (2000) 0.82
Age as a prognostic factor in breast cancer. Anticancer Res (1998) 0.82
Basic fibroblast growth factor (bFGF): mitogenic activity and binding sites in human breast cancer. J Steroid Biochem Mol Biol (1992) 0.82
Plasma acid and alkaline phosphatase in patients with breast cancer. Anticancer Res (1991) 0.81
[Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France]. Rev Epidemiol Sante Publique (2005) 0.81
The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer. Clin Cancer Res (1998) 0.81
Type I insulin-like growth factor receptors in human colorectal cancer. Eur J Cancer (1995) 0.80
Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion. Int J Biol Markers (2008) 0.80
Absence of germline mutations of exons 5 to 8 of the P53 gene in 26 breast cancer families from the north of France. Eur J Cancer (1993) 0.80
Prognostic value of tumoral sialyltransferase expression and circulating E-selectin concentrations in node-negative breast cancer patients. Int J Biol Markers (2003) 0.80
Prolactin receptors in human breast cancer. Eur J Cancer Clin Oncol (1982) 0.80
Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study Group. Eur J Cancer (1995) 0.79
Transferrin receptors in cultured breast cancer cells. J Cancer Res Clin Oncol (1985) 0.79
A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer. Ann Oncol (2001) 0.79
Correlation between prolactin receptors (PRL R), estradiol (ER) and progesterone receptors (PgR) in human breast cancer. Eur J Cancer Clin Oncol (1986) 0.79
Aqueous flare induced by heparin-surface-modified poly(methyl methacrylate) and acrylic lenses implanted through the same-size incision in patients with diabetes. J Cataract Refract Surg (2001) 0.79
[Economic assessments of head and neck cancers: a review]. Bull Cancer (2001) 0.78
Subclass restriction of the antiidiotypic antibody response in the rat. Ann Immunol (Paris) (1984) 0.78
[Cost of early management of chronic inflammatory intestinal disease]. Gastroenterol Clin Biol (1999) 0.78
Insulin-like growth factor 1 receptors in human breast tumour: localisation and quantification by histo-autoradiographic analysis. Br J Cancer (1992) 0.78
Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future research. Eur J Cancer (1994) 0.78
Cost and cost effectiveness of the mechanical and pharmacologic bridge to transplantation. ASAIO Trans (1992) 0.78
Factors associated with recurrence of catheter-related bloodstream infections in home parenteral nutrition patients. Eur J Clin Microbiol Infect Dis (2012) 0.78
Stimulation of DNA synthesis by prolactin in human breast tumor explants. Relation to prolactin receptors. Anticancer Res (1984) 0.78
Platinum concentration in human tumors of head and neck, uterine cervix, and breast following treatment with cisplatin. Cancer Chemother Pharmacol (1985) 0.78
Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study. Ann Oncol (1994) 0.78
5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomized study. Eur J Cancer (1994) 0.78
Knowledge, self-management, compliance and quality of life in asthma: a cross-sectional study of the French version of the Asthma Quality of Life Questionnaire. Qual Life Res (1998) 0.78
Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day. Eur J Cancer Clin Oncol (1985) 0.77